

## APPENDIX 2: Cancer Epidemiology Information Northern Ireland

Table 1: Summary statistics for cancer in Northern Ireland

	Cases per year (2003-2007)	Median age at diagnosis (2003-2007)	Prevalence - Number of patients diagnosed since 1993 who were still alive at end of 2007	Deaths per year (2004-2008)	Potential years of life lost each year (2004-2008)
<b>Head and Neck</b>	245	64	1,402	79	688
<b>Oral</b>	160	64	828	53	526
<b>Nose and Sinuses</b>	14	68	76	3	29
<b>Larynx</b>	71	64	498	23	134
<b>Oesophagus</b>	168	70	353	159	1,139
<b>Stomach</b>	228	73	539	158	821
<b>Small intestine</b>	21	65	98	8	95
<b>Colorectal</b>	1,039	71	5,489	433	2,613
<b>Colon</b>	668	72	3,505	292	1,630
<b>Rectum</b>	371	69	1,984	141	983
<b>Liver</b>	66	72	83	81	549
<b>Gallbladder</b>	56	74	106	19	70
<b>Pancreas</b>	178	72	134	190	1,276
<b>Lung</b>	945	71	1,367	853	5,209
<b>Bone</b>	16	36	112	9	257
<b>Melanoma</b>	236	59	2,156	48	487
<b>Non-melanoma skin</b>	2,513	72	22,762	17	45
<b>Mesothelioma</b>	46	72	57	38	225
<b>Connective and soft tissue</b>	42	61	268	15	198
<b>Breast</b>	1,082	61	9,281	309	2,975
<b>Cervix</b>	85	40	795	26	343
<b>Uterus</b>	184	64	1,297	39	215
<b>Ovary</b>	182	64	967	123	1,008
<b>Prostate</b>	829	70	4,736	226	452
<b>Testis</b>	59	35	749	1	55
<b>Kidney</b>	206	68	1,044	96	677
<b>Bladder</b>	210	74	1,110	91	331
<b>Brain</b>	122	58	454	88	1,529
<b>Thyroid</b>	44	53	482	9	69
<b>Lymphoma</b>	315	65	2,068	112	765
<b>Hodgkin's lymphoma</b>	47	42	436	9	120
<b>Non-Hodgkin's lymphoma</b>	268	67	1,632	104	645
<b>Myeloma</b>	124	71	475	73	330
<b>Leukaemia</b>	159	66	804	94	765
<b>Other</b>	430	74	1,106	420	2,217
<b>All cancers</b>	9,829	69	60,294	3,814	25,404

**Table 2: Relative survival for patients with cancer in Northern Ireland**

	1-year relative survival (diagnosed 2003-2006)		5-year relative survival (diagnosed 1998-2002)	
	Male	Female	Male	Female
Head and Neck	79.3% (75.5%, 82.6%)	77.8% (71.8%, 82.7%)	57.3% (52.9%, 61.5%)	50.0% (43.4%, 56.5%)
Oesophagus	37.2% (32.1%, 42.3%)	30.3% (23.4%, 37.6%)	11.5% (8.5%, 15.0%)	14.9% (10.8%, 19.8%)
Stomach	35.7% (31.2%, 40.1%)	34.8% (29.3%, 40.4%)	16.3% (13.4%, 19.4%)	16.9% (13.4%, 20.9%)
Colorectal	74.8% (72.6%, 76.8%)	70.8% (68.4%, 73.1%)	50.4% (47.9%, 52.9%)	53.7% (51.1%, 56.2%)
Liver	23.2% (16.0%, 31.2%)	27.9% (17.3%, 39.6%)	6.3% (2.8%, 11.8%)	4.4% (1.4%, 10.0%)
Pancreas	14.8% (10.7%, 19.5%)	12.0% (8.4%, 16.1%)	1.5% (0.5%, 3.5%)	1.4% (0.5%, 3.5%)
Lung	26.5% (24.5%, 28.5%)	30.0% (27.4%, 32.6%)	8.5% (7.3%, 9.7%)	9.3% (7.8%, 10.9%)
Melanoma	94.4% (90.8%, 97.0%)	99.3% (97.3%, 100.5%)	84.1% (78.6%, 89.0%)	93.6% (89.8%, 96.8%)
Breast		94.9% (94.0%, 95.7%)		80.3% (78.9%, 81.8%)
Cervix		88.0% (83.5%, 91.4%)		69.1% (64.0%, 73.6%)
Uterus		87.9% (84.9%, 90.4%)		73.1% (69.0%, 76.9%)
Ovary		68.5% (64.7%, 71.9%)		42.8% (39.3%, 46.3%)
Prostate	93.6% (92.4%, 94.7%)		71.0% (68.5%, 73.5%)	
Testis	97.4% (94.2%, 99.0%)		97.0% (93.5%, 99.1%)	
Kidney	67.9% (62.9%, 72.4%)	68.5% (62.4%, 73.9%)	48.0% (42.8%, 53.1%)	47.7% (41.5%, 53.8%)
Bladder	79.7% (75.7%, 83.3%)	66.8% (59.8%, 73.0%)	59.9% (55.1%, 64.6%)	41.3% (34.6%, 48.1%)
Brain	40.7% (33.9%, 47.3%)	41.6% (33.6%, 49.5%)	19.8% (15.5%, 24.5%)	21.1% (15.9%, 26.8%)
Lymphoma	75.8% (71.8%, 79.4%)	73.2% (69.2%, 76.9%)	55.0% (50.7%, 59.2%)	57.7% (53.6%, 61.7%)
Myeloma	69.0% (62.6%, 74.7%)	79.2% (72.2%, 84.8%)	31.1% (25.0%, 37.6%)	35.0% (28.0%, 42.3%)
Leukaemia	62.2% (55.9%, 67.9%)	56.8% (49.9%, 63.2%)	33.7% (28.6%, 39.1%)	37.1% (30.8%, 43.5%)
Other	41.5% (38.4%, 44.7%)	41.6% (38.7%, 44.5%)	20.1% (18.0%, 22.3%)	26.5% (24.3%, 28.8%)

Note: Figures in brackets represent the 95% confidence interval for the survival rate.

**Table 3: Patients Discussed at Multi-Disciplinary Team Meetings (MDT)**

	% Patients discussed		
	1996	2001	2005/6*
Stomach	2%	16%	42%
Oesophagus	1%	32%	61%
Lung	19%	47%	64%
Colon	1%	18%	57%
Rectum	1%	31%	67%
Prostate	1%	4%	59%
Breast	4%	26%	55%
Ovary	1%	40%	-
Pancreas	-	13%	-

\* Stomach and oesophagus 2005, all other cancers 2006

**Table 4: Patients with cancer staged**

	% Patients with stage recorded		
	1996	2001	2005/6*
<b>Stomach</b>	53%	62%	86%
<b>Oesophagus</b>	41%	49%	78%
<b>Lung</b>	64%	65%	82%
<b>Colon</b>	90%	92%	96%
<b>Rectum</b>	83%	84%	85%
<b>Prostate</b>	29%	61%	72%
<b>Breast</b>	91%	87%	93%
<b>Ovary</b>	84%	79%	-
<b>Pancreas</b>	-	42%	-

\* Stomach and oesophagus 2005, all other cancers 2006

**Table 5: Patients referred to oncologists**

	% Patients referred to oncologists		
	1996	2001	2005/6*
<b>Stomach</b>	13%	38%	57%
<b>Oesophagus</b>	27%	27%	66%
<b>Lung</b>	53%	63%	64%
<b>Colorectal</b>	41%	59%	60%
<b>Prostate</b>	12%	39%	59%
<b>Breast</b>	70%	87%	93%
<b>Ovary</b>	59%	79%	-
<b>Pancreas</b>	-	33%	-

\* Stomach and oesophagus 2005, all other cancers 2006

**Table 6: Patients referred to Palliative Care Specialists**

	% Patients referred to Palliative Care Specialists		
	1996	2001	2005/6*
<b>Stomach</b>	6%	24%	37%
<b>Oesophagus</b>	12%	29%	44%
<b>Lung</b>	4%	27%	29%
<b>Colorectal</b>	3%	45%	20%
<b>Prostate</b>	1%	3%	3%
<b>Breast</b>	2%	3%	4%
<b>Ovary</b>	-	20%	-
<b>Pancreas</b>	-	15%	-

\* Stomach and oesophagus 2005, all other cancers 2006

**Table 7: Patients whose GP discharge letter included a management plan**

	% Patients whose GP letter included a management plan		
	1996	2001	2005/6*
<b>Stomach</b>	79%	80%	41%
<b>Oesophagus</b>	94%	92%	88%
<b>Lung</b>	77%	92%	96%
<b>Colorectal</b>	77%	90%	97%
<b>Prostate</b>	97%	92%	96%
<b>Breast</b>	75%	94%	90%
<b>Ovary</b>	79%	95%	-
<b>Pancreas</b>	-	68%	-

\* Stomach and oesophagus 2005, all other cancers 2006

**Table 8: Patients whose GP discharge letter recorded *Diagnosis discussed with patient***

	% Patients whose GP letter recorded diagnosis discussed with patient		
	1996	2001	2005/6*
<b>Stomach</b>	49%	50%	94%
<b>Oesophagus</b>	50%	57%	90%
<b>Lung</b>	40%	65%	70%
<b>Colorectal</b>	26%	52%	82%
<b>Prostate</b>	57%	60%	63%
<b>Breast</b>	92%	98%	82%
<b>Ovary</b>	36%	51%	
<b>Pancreas</b>		49%	

\* Stomach and oesophagus 2005, all other cancers 2006